Pasithea Therapeutics (KTTA) EBITDA Margin (2022)
Pasithea Therapeutics recorded quarterly EBITDA Margin of 2065.45% in Q4 2022, up 3.29% quarter-over-quarter from 2135.62% in Q3 2022.
Pasithea Therapeutics' EBITDA Margin history runs 1 years deep, the most recent figure standing at 2065.45% for Q4 2022.
- In Q4 2022, EBITDA Margin changed N/A year-over-year to 2065.45%; the TTM figure through Dec 2022 stood at 2862.25% (changed N/A YoY), while the FY2022 annual figure was 2862.25%, up 1163836.0% from the prior year.
- EBITDA Margin came in at 2065.45% for Q4 2022 at Pasithea Therapeutics, up from 2135.62% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 2065.45% in Q4 2022 to a low of 19935.05% in Q2 2022.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -6.43% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 38.10% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 18.35% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 17.24% |
| 10 | Pasithea Therapeutics | 17.41 Mn | 17.41 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | -2,065.45% |
| Sep 30, 2022 | -2,135.62% |
| Jun 30, 2022 | -19,935.05% |
| Mar 31, 2022 | -11,559.18% |